{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05543681",
            "orgStudyIdInfo": {
                "id": "IGC-AD1-P2 BIDAG"
            },
            "organization": {
                "fullName": "India Globalization Capital Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's",
            "officialTitle": "A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants With Dementia Due to Alzheimer's Disease",
            "acronym": "IGC-AD1-P2",
            "therapeuticArea": [
                "Mental Health",
                "Other",
                "Neurology"
            ],
            "study": "igc-trial-on-agitation-in-dementia-due-to-alzheimer-s"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-10-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-14",
            "studyFirstSubmitQcDate": "2022-09-14",
            "studyFirstPostDateStruct": {
                "date": "2022-09-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-05",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "IGC Pharma LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.",
            "detailedDescription": "This is a placebo-controlled, multi-site, parallel, double blind, randomized study. Enrollment is open for Participants ages 60 and above with mild to severe dementia due to Alzheimer's Disease, with established symptomatological Agitation, for a minimum of two weeks prior to enrollment, with Agitation due to other etiologies, or recent, or transient Agitation symptoms ruled out. Clinical Agitation is established with a baseline NPI-12 (Agitation Domain only) score \u2265 4 as well as meeting the IPA criteria for Agitation.\n\nThe medication is titrated to BID over two days and down over two days at End of Trial (EOT). Caregivers will monitor and record in a logbook vitals daily using Sponsor provided scales and logbook.\n\nSafety will be monitored with daily calls to the Participant/Caregiver dyad for the first four days followed by calls every third day till EOT. Week two is an on-site visit with week-four being optional.\n\nBoth solicited AEs and non-solicited AEs will be monitored, assessed, graded, and tabulated. Solicited AEs include the following: somnolence, falls, dizziness, asthenia, nausea, suicidal ideation, tachycardia, bradycardia, hypertension and hypotension, and BMI.\n\nThe primary objective of the study is to assess the efficacy of IGC-AD1 on Agitation as scored by the CMAI between baseline and EOT with the secondary objective being acute efficacy as measured by the CMAI between baseline and week two. There are several exploratory objectives included elsewhere. The trial will also have blood draws for sparse Pharmacokinetics (PK)."
        },
        "conditionsModule": {
            "conditions": [
                "Alzheimer Disease",
                "Agitation,Psychomotor",
                "Depression",
                "Anxiety",
                "Memory Impairment",
                "Care Giving Burden",
                "NPS",
                "Agitated; State, Acute Reaction to Stress",
                "Aggression",
                "Aggressive Outburst"
            ],
            "keywords": [
                "Cannabis",
                "Tetrahydrocannabinol",
                "THC",
                "Melatonin",
                "Alzheimer's",
                "Marijuana",
                "Hemp",
                "Agitation",
                "Dementia",
                "Depression",
                "Anxiety",
                "Memory",
                "NPI",
                "CMAI",
                "Dronabinol"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Multi-site, Randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to severe dementia from Alzheimer's and symptomatological Agitation.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "maskingDescription": "Double-blind for study site and participants",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 164,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Active Comparator: IGC-AD1Active",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "IGC-AD1 Active Treatment THC plus another API plus excipients.",
                    "interventionNames": [
                        "Drug: Agitation management in Alzheimer's disease (IGC-AD1-Active)"
                    ]
                },
                {
                    "label": "Placebo Comparator: IGC-AD1 Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "IGC-AD1 Placebo, similar to Active in color, taste, and texture, with excipients but without APIs.",
                    "interventionNames": [
                        "Drug: Agitation management in Alzheimer's disease (IGC-AD1-Placebo)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Agitation management in Alzheimer's disease (IGC-AD1-Active)",
                    "description": "A non-sterile solution for oral administration.",
                    "armGroupLabels": [
                        "Active Comparator: IGC-AD1Active"
                    ],
                    "otherNames": [
                        "Active Study Drug",
                        "Study Drug",
                        "Active",
                        "IGC-AD1 Active"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Agitation management in Alzheimer's disease (IGC-AD1-Placebo)",
                    "description": "A non-sterile solution for oral administration similar in color and texture to the Active.",
                    "armGroupLabels": [
                        "Placebo Comparator: IGC-AD1 Placebo"
                    ],
                    "otherNames": [
                        "IGC-AD1 Placebo",
                        "Non-active study drug",
                        "IGC-AD1 Non-Active",
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Agitation",
                    "description": "Change in mean Cohen Mansfield Agitation Inventory (CMAI) score",
                    "timeFrame": "Baseline to week six"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Acute Agitation",
                    "description": "Change in mean Cohen Mansfield Agitation Inventory (CMAI) score",
                    "timeFrame": "Baseline to week two"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Agitation at week four",
                    "description": "Change in mean Cohen Mansfield Agitation Inventory (CMAI) score",
                    "timeFrame": "Baseline to week four"
                },
                {
                    "measure": "Participant overall wellbeing",
                    "description": "Change in the Clinical Global Impression Scale (CGI)",
                    "timeFrame": "Baseline to weeks two and six"
                },
                {
                    "measure": "Participant executive functions",
                    "description": "Change in Mini-Mental State Examination (MMSE2) score",
                    "timeFrame": "Baseline to week six"
                },
                {
                    "measure": "Depression",
                    "description": "Change in mean Cornell Scale for Depression in Dementia (CSDD) score",
                    "timeFrame": "Baseline to weeks two, four, and six"
                },
                {
                    "measure": "Neuropsychiatric symptoms",
                    "description": "Change in mean Neuropsychiatric Inventory (NPI-12) score",
                    "timeFrame": "Baseline to weeks two, four, and six"
                },
                {
                    "measure": "Participant quality of life",
                    "description": "Change in mean Quality of Life in Alzheimer's Disease (QOL-AD) score",
                    "timeFrame": "Baseline to weeks two, four and six"
                },
                {
                    "measure": "Caregiver burden",
                    "description": "Change in mean Zarit Burden Interview (ZBI) score",
                    "timeFrame": "Baseline to weeks two and six"
                },
                {
                    "measure": "Psychotropic drugs",
                    "description": "Change in type and dosage of psychotropic drugs",
                    "timeFrame": "Baseline to six weeks"
                },
                {
                    "measure": "CYP2C9 polymorphisms on agitation",
                    "description": "Change in mean Cohen Mansfield Agitation Inventory (CMAI) score for each type of metabolizer group (\\*1/\\*1, \\*1/\\*3, etc.)",
                    "timeFrame": "Baseline to weeks two, four and six"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "To be eligible to participate in this study, the participant must meet all the following criteria:\n\nInclusion Criteria\n\n1. Participant and/or Caregiver must provide a signed and dated ICF prior to any study procedures.\n2. Must have a Caregiver who is able and willing to comply with all required study procedures.\n3. The Caregiver must be known to the Participant and must be able to use electronic devices such as a cell phone, video conference over a laptop or cell phone, weighing scale, and be able to learn to take blood pressure, among others.\n4. Based on local practice, Participants that cannot consent may have Caregiver's consent provided the Caregiver has among others a) Power of Attorney, b) is a spouse, or c) a sibling or d) a child or e) a close relation. The practice of accepting consent must be consistent with established practice at the site and jurisdiction.\n5. Participants must consent to CYP450 and apolipoprotein E (ApoE) genotyping, and pharmacokinetics.\n6. Diagnosis of AD by NIA-AA criteria\n7. Clinically significant Agitation assessed by:\n\n   1. NPI (Agitation) \u2265 4\n   2. The presence of clinically significant, persistent Agitation based on the IPA definition (Appendix C) rather than those with recent onset and occasional symptoms, and\n   3. Agitation not attributable to another psychiatric disorder, suboptimal care conditions, other underlining medical condition, or the physiological effects of a substance.\n8. Negative drug screen, except for benzodiazepines if Participant has been using them in stable doses for at least 3 months before screening.\n9. All medications used for behavioral symptoms should be consistent for at least 3 months before screening, with allowance for dose changes up to 25%.\n10. Women must be of no childbearing potential (postmenopausal, defined as cessation of menses for at least 12 months, without an alternative medical cause for amenorrhea) or surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation)).\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\nExclusion Criteria\n\n1. Prior adverse reaction to cannabinoids or to any component of Study Drug (IGC-AD1 and placebo): THC, melatonin, honey, curcumin, ethyl alcohol, vitamin-E TPGS, ascorbic acid, water, tween-80, and rutin.\n2. Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease, which might confound assessment of safety outcomes.\n3. History of seizures, schizophrenia, or bipolar disorder.\n4. Has participated in an investigational drug or device study within 30 days prior to study start.\n5. Urine drug screen positive for drug use, except for benzodiazepines if Participant was using them previously and their dose had remained stable for at least 3 months before screening.\n6. History of Alcohol and Drug use disorder, within one year prior to enrollment.\n7. Hypertension: Participants with a history of uncontrolled hypertension as determined by the PI and Participants with a hypertensive crisis in the six months prior to enrollment.\n8. Falls: Participants with a history of recurrent falls defined as more than two falls in the six-month period prior to enrollment and a history of falls resulting in injuries or associated with a new acute illness, loss of consciousness, fever, or abnormal blood pressure (Fuller et al., 2000).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "60 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Evelyn Gutierrez",
                    "role": "CONTACT",
                    "phone": "3013394270",
                    "email": "egutierrez@igcpharma.com"
                },
                {
                    "name": "Margarita Venegas, MS",
                    "role": "CONTACT",
                    "email": "mvenegas@igcpharma.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Dr. Saadia Shahnawaz, MD",
                    "affiliation": "IGC Pharma LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Site 700",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Florida",
                    "zip": "32940",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.08363,
                        "lon": -80.60811
                    }
                },
                {
                    "facility": "Site 1200",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33125",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Site 1100",
                    "status": "RECRUITING",
                    "city": "Port Charlotte",
                    "state": "Florida",
                    "zip": "33952",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.97617,
                        "lon": -82.09064
                    }
                },
                {
                    "facility": "Site 400",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21237",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Site 800",
                    "status": "WITHDRAWN",
                    "city": "Newton",
                    "state": "Massachusetts",
                    "zip": "02459",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33704,
                        "lon": -71.20922
                    }
                },
                {
                    "facility": "Site 900",
                    "status": "RECRUITING",
                    "city": "Amherst",
                    "state": "New York",
                    "zip": "02459",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site 900",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.97839,
                        "lon": -78.79976
                    }
                },
                {
                    "facility": "Site 1400",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73112",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "Site 1000",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "ON M6A 2E1",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Site 300",
                    "status": "WITHDRAWN",
                    "city": "Montr\u00e9al",
                    "state": "Quebec",
                    "zip": "H3Z 2Y5",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Site 1300",
                    "status": "RECRUITING",
                    "city": "Montr\u00e9al",
                    "state": "Quebec",
                    "zip": "H4H 1R3",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Site 100",
                    "status": "RECRUITING",
                    "city": "Bayam\u00f3n",
                    "zip": "00961",
                    "country": "Puerto Rico",
                    "geoPoint": {
                        "lat": 18.39856,
                        "lon": -66.15572
                    }
                },
                {
                    "facility": "Site 200",
                    "status": "RECRUITING",
                    "city": "Bayam\u00f3n",
                    "zip": "00961",
                    "country": "Puerto Rico",
                    "geoPoint": {
                        "lat": 18.39856,
                        "lon": -66.15572
                    }
                },
                {
                    "facility": "Site 500",
                    "status": "RECRUITING",
                    "city": "Rio Piedras",
                    "zip": "00935",
                    "country": "Puerto Rico",
                    "geoPoint": {
                        "lat": 18.39745,
                        "lon": -66.04989
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000544",
                    "term": "Alzheimer Disease"
                },
                {
                    "id": "D000003704",
                    "term": "Dementia"
                },
                {
                    "id": "D000011595",
                    "term": "Psychomotor Agitation"
                },
                {
                    "id": "D000003863",
                    "term": "Depression"
                },
                {
                    "id": "D000000374",
                    "term": "Aggression"
                },
                {
                    "id": "D000084802",
                    "term": "Caregiver Burden"
                },
                {
                    "id": "D000040701",
                    "term": "Stress Disorders, Traumatic, Acute"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001526",
                    "term": "Behavioral Symptoms"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000024801",
                    "term": "Tauopathies"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000019965",
                    "term": "Neurocognitive Disorders"
                },
                {
                    "id": "D000096762",
                    "term": "Aberrant Motor Behavior in Dementia"
                },
                {
                    "id": "D000020820",
                    "term": "Dyskinesias"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000011596",
                    "term": "Psychomotor Disorders"
                },
                {
                    "id": "D000019954",
                    "term": "Neurobehavioral Manifestations"
                },
                {
                    "id": "D000013315",
                    "term": "Stress, Psychological"
                },
                {
                    "id": "D000040921",
                    "term": "Stress Disorders, Traumatic"
                },
                {
                    "id": "D000068099",
                    "term": "Trauma and Stressor Related Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3885",
                    "name": "Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7058",
                    "name": "Depression",
                    "asFound": "Depression",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7061",
                    "name": "Depressive Disorder",
                    "relevance": "LOW"
                },
                {
                    "id": "M4324",
                    "name": "Anxiety Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5449",
                    "name": "Marijuana Abuse",
                    "relevance": "LOW"
                },
                {
                    "id": "M2480",
                    "name": "Caregiver Burden",
                    "asFound": "Care Giving Burden",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6904",
                    "name": "Dementia",
                    "asFound": "Dementia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M24908",
                    "name": "Stress Disorders, Traumatic, Acute",
                    "asFound": "Acute Reaction to Stress",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14452",
                    "name": "Psychomotor Agitation",
                    "asFound": "Agitation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3724",
                    "name": "Aggression",
                    "asFound": "Aggression",
                    "relevance": "HIGH"
                },
                {
                    "id": "M24916",
                    "name": "Stress Disorders, Traumatic",
                    "relevance": "LOW"
                },
                {
                    "id": "M4818",
                    "name": "Behavioral Symptoms",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23002",
                    "name": "Tauopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21836",
                    "name": "Neurocognitive Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M3259",
                    "name": "Aberrant Motor Behavior in Dementia",
                    "relevance": "LOW"
                },
                {
                    "id": "M22574",
                    "name": "Dyskinesias",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M14453",
                    "name": "Psychomotor Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21826",
                    "name": "Neurobehavioral Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M16105",
                    "name": "Stress, Psychological",
                    "relevance": "LOW"
                },
                {
                    "id": "M17685",
                    "name": "Wounds and Injuries",
                    "relevance": "LOW"
                },
                {
                    "id": "M222",
                    "name": "Trauma and Stressor Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T2192",
                    "name": "Familial Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M16527",
                    "name": "Dronabinol",
                    "relevance": "LOW"
                },
                {
                    "id": "M11533",
                    "name": "Melatonin",
                    "relevance": "LOW"
                },
                {
                    "id": "T410",
                    "name": "Melatonin",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "Ot",
                    "name": "Other Dietary Supplements"
                }
            ]
        }
    },
    "hasResults": false
}